Digital therapeutics clinical trials enable collection and analysis of data in real time, but considerations like standardization of analysis, trial endpoints and placebo controls are critical, experts at the DTx East conference in Boston said. Read full article here.
PALO ALTO, Calif. and CHICAGO, Sept. 10, 2019 /PRNewswire/ — Cognoa, a company at the forefront of pediatric behavioral health, and EVERSANA™, the leading independent provider of global commercial services to the life science industry, today announced a partnership to advance the industry standard by which digital medicines will be ordered, dispensed, and covered by insurance. By leveraging the existing healthcare infrastructure utilized by pharmaceutical companies…
Google Glass has been used for everything from opera glasses to helping workers on factory floors. More recently, it’s been used to help children diagnosed with autism spectrum disorder (ASD) to better recognize emotional cues in conversation. Now a company called Cognoa is licensing that software to bring it to more kids. Read full article here.
PALO ALTO, Calif., April 10, 2019 (GLOBE NEWSWIRE) — Cognoa, a company at the forefront of digital behavioral health for children, today announces it has exclusively licensed technology from the Stanford University School of Medicine to accelerate development and worldwide commercialization of a novel digital therapeutic for children with autism spectrum disorder (ASD). Underscoring the need for earlier access to personalized…
US FDA recently granted Cognoa’s autism diagnostic device a Breakthrough Device designation to accelerate its efforts to get the first FDA-cleared medical device for the early diagnosis of autistic spectrum disorder (ASD) to market. Read full article here.
Palo Alto, Calif.-based Cognoa Inc. received breakthrough device designations from the U.S. FDA for its digital diagnostic and digital therapeutic devices for autism. Read full article here.
FDA has granted breakthrough designations to Cognoa’s digital autism diagnostic and therapeutic devices, the company announced Wednesday. The devices are designed to enable physicians to diagnose autism spectrum disorder (ASD) earlier and improve the social skills and responsiveness of children with the condition. Read full article here.
Under the program, the FDA will provide Cognoa with priority review and interactive communication regarding device development and clinical trial protocols, through to commercialization decisions. Read full article here.
PALO ALTO, Calif., Feb. 06, 2019 (GLOBE NEWSWIRE) — Cognoa, a company at the forefront of digital behavioral health for children, today announces it has received Breakthrough Device designations from the U.S. Food and Drug Administration (FDA) for its lead products, the first digital diagnostic and digital therapeutic devices for autism. These products are the foundation of Cognoa’s precision health platform…
Email Print Friendly ShareJanuary 08, 2019 09:03 ET | Source: Cognoa PALO ALTO, Calif., Jan. 08, 2019 (GLOBE NEWSWIRE) — Cognoa, a digital behavioral health company, announced today that Cambia Health Solutions, Inc. (Cambia) is incorporating Cognoa’s evidence-based platform within its subsidiary health plans. Cognoa provides support for employees caring for children older than one. Cognoa offers reliable guidance on day-to-day challenges and personalized resources that enable…
